New Antiplatelet Agents: Platelet GPIIb/llla Antagonists^[*]

• 

Supported by grant 19278 from the National Heart, Lung, and Blood Institute

• References

• 1 Antiplatelet trialists’ collaboration: Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients.. Br Med J 1994; 308: 81-106
• 2 Coller BS. Antiplatelet agents in the prevention and therapy of thrombosis. Ann Rev Med 1992; 43: 171-180
• 3 Coller BS. Platelets and thrombolytic therapy. N Eng J Med 1990; 322: 33-42
• 4 Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein Ilb-IIIa complex. Blood 1988; 71: 831-843
• 5 George JN, Caen JP, Nurden AT. Glanzmann thrombasthenia: The spectrum of clinical disease. Blood 1990; 75: 1383-1395
• 6 Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE. (ed). The Heart and Cardiovascular System. Raven Press; New York: 1992. pp. 219-273
• 7 Hynes RO. Integrins: versatility, modulation and signalling in cell adhesion. Cell 1992; 69: 11-25
• 8 Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein Ilb/IIIa: Member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 1986; 231: 1559-1562
• 9 Cook NS, Kottirsch G, Zerwes H-G. Platelet glycoprotein Ilb/IIIa antagonists. Drugs of Future 1994; 19: 135-159
• 10 Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of integrins. Medicinal Research Reviews 1994; 14: 195-228
• 11 Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993; 5: 864-868
• 12 Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 1991; 77: 75-83
• 13 Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet GPIIb/ Ilia as antithrombotic agents. Ann NY Acad Sci 1991; 614: 193-213
• 14 Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein Ilb/IIIa complex. J Clin Invest 1985; 76: 101-108
• 15 Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wange AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein Ilb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-1764
• 16 Simoons ML, de Boer MJ, van den Brand MJ, van Mittenburg AJ, Hoorntje JC, Hegndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen K, Stibbe J, de Feyter PJ. the European Cooperative study group: Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603
• 17 Coller BS. Inhibitors of the platelet glycoprotein Ilb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coronary Art Dis 1992; 3: 1016-1029
• 18 The EPIC investigators: Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty.. N Eng J Med 1994; 330: 956-961
• 19 Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. on behalf of the EPIC investigators: Randomized trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886
• 20 Lincoff AM, Tcheng JE, Bass TA, Popma JJ, Teirstein PS, Topol EJ, Kleiman NS, Weisman HF, Musco NH, Cabot CF, Berdan LG, Califf R. A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with platelet GPIIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization (abstr). J Am Coll Cardiol. 1995 in press.
• 21 Coller BS, Kutok JL, Scudder LE, Galanakis DK, West SM, Rudomen GS, Springer KT. Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets: Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. J Clin Invest 1993; 92: 2796-2806
• 22 Walsh PN. Platelet-coagulant protein interaction. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Colman RW, Hirsh J, Marder VJ, Salzman EW. (eds). J.B. Lippincott; Philadelphia: 1994. pp. 629-651
• 23 Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF. Topol EJ for the EPIC study investigators: Activated clotting time is increased during coronary interventions with platelet glycoprotein Ilb/IIIa integrin blockade: results from the EPIC trial. Am J Cardiol. 1995 in press.
• 24 Ammar T, Sarier K, Coller BS. Activated clotting time of heparinized blood is increased by in vitro platelet glycoprotein Ilb/IIIa receptor blockade with antibody c7E3 Fab. abstr. Thromb Haemostas. 1995 in press
• 25 Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemostas 1993; 70: 617-624
• 26 Reverter JC, Kessels H, Beguin S, Kumar R, Hemker HC, Coller BS. Platelet glycoprotein Ilb/IIIa inhibition decreases thrombin generation induced by tissue factor (abstr.). Blood 1994; 84: 470a.
• 27 Schwartz SM. Serum-derived growth factor is thrombin. J Clin Invest 1993; 91: 4
• 28 Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking avlS3 integrin with a small peptide antagonist G/>enGRGDSPCA. J Vase Surg 1994; 19: 125-134
• 29 Matsuno H, Stassen JM, Vermylen J, Deckmyn H. nhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-2206
• 30 Coller BS, Scudder LE, Lang D. A rapid, whole blood, bedside assay to monitor platelet glycoprotein (GP) Ilb/IIIa blockade (abstr.). Blood 1994; 84: 474a
• 31 Kleiman NS, Ohman ME, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: Results of the TAMI 8 pilot study. J Am Coll 1993; 22: 381-389
• 32 Schulman SP, Goldscmit-Clermont PJ, Navetta FI. et al:Integrelin in unstable angina: a double-blind randomized trial (abstr.). Circulation 1993; 88: 1-608
• 33 Tcheng JE, Ellis SG, Kleiman NS. et ah: A multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein Ilb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 1995 in press
• 34 Theroux P, Kouz S, Knudtson M, Kells C, Nasmith J, Roy L, Dalle Ave S, Steine B, Xiao Z, Rapold HJ. A randomized double-blind controlled trial with the non-peptidic platelet GP Ilb/IIIa antagonist RO 44-9883 in unstable angina (abstr.). Circulation 1994; 90: 1-232
• 35 Ohman M, Kleiman N, Talley D, Gacioch G, Navetta FI, Carney RJ, Worley S, Anderson V, Cohen M, Kereiakes D, Joseph D, Sigmon KN. Topol EJ for the IMPACT-AMI study group: Simultaneous platelet glycoprotein Ilb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction (abstr.). Circulation 1994; 90: 1-564
• 36 Keriakes D, Kleiman N, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton J, Weaver WD, McKee D, Sax FL. A dosing study in high risk PTCA of MK-383, a platelet Ilb/IIIa antagonist (abstr.). Circulation 1994; 90: 1-21
• 37 Theroux P, White H, David D, Van de Werf F, Nienaber CA, Charbonnier B, Erhardt L, Gill J, Hillis WS, Jennings G, Tan L- B, Deschenes N, Fitzpatrick V, Sax FL. A heparin-controlled study of MK-383 in unstable angina (abstr.). Circulation 1994; 90: 1-231
• 38 Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: New insights from an historical perspective. Sem Hemat 1994; 31: 301-311